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T
he traditional, low-cost mainstay 
drugs for malaria, chloroquine 
(CQ) and sulphadoxine-
pyrimethamine (SP), have a very 
limited lifetime left in terms of their 
clinical usefulness. These drugs have 
been relatively ineffective in Asia for 
two decades, and rising drug resistance 
levels have now also rendered them 
ineffective in many sub-Saharan African 
countries [1]. Artemisinin drugs, such 
as artesunate and artemether, derived 
from the Chinese herb Artemisia annua, 
are rapidly being adopted as standard 
treatments in Africa, in the hope 
that effective treatment will assist in 
reversing the apparently increasing 
death rates in African children [2]. 
The Impact of Artemisinin 
Derivatives on Gametocytes
In the most severe form of human 
malaria, Plasmodium falciparum, 
adequate treatment of a malaria 
attack does not necessarily prevent the 
infected person from transmitting the 
disease to others. Mosquitoes become 
infected by ingesting mature sexual 
stages, known as gametocytes, which 
take around ten days to develop. 
Mature gametocytes present at the 
time of treatment may be unaffected, 
and parasites already committed to 
gametogenesis at the time of treatment 
will continue their development. 
Therefore, infectious gametocytes may 
be present in the blood for many days 
after the patient has been treated and 
feels better. Gametocytes responsible 
for such “post-treatment transmission” 
are more likely to carry and spread 
drug-resistant alleles [3]. 
Trials showed that adding three 
days of the artemisinin derivative 
artesunate to existing 
antimalarial treatments 
led to a marked 
reduction in the number 
of gametocytes in the 
month following the 
treatment [4]. Whether 
this translates to an 
impact on transmission 
is less clear: in an area 
of low transmission 
in western Thailand, 
the introduction of 
artesunate in 1994 
coincided with a 
sustained decrease in 
incidence of malaria [5]. 
However, infectiousness 
of patients to mosquitoes 
in this study was not measured 
directly, and the association of drug 
introduction and incidence reduction 
may have been coincidental. 
A randomized controlled study 
by Sutherland and colleagues in this 
month’s PLoS Medicine [6] shows 
conclusively that a six-dose course 
of artemether-lumefantrine (co-
artemether) given to children with P. 
falciparum malaria in Gambia reduces 
gametocyte prevalence, duration of 
gametocyte carriage, and infectiousness 
to mosquitoes, compared to dual 
treatment with CQ and SP (CQ/SP). 
Presumably owing to lower gametocyte 
density, none of the artemether-
lumefantrine-treated gametocyte 
carriers were infectious on day 7 after 
treatment, compared to 37% of the 
CQ/SP-treated children. The results 
also show that artemether-lumefantrine 
has a speciﬁ  c action against developing 
gametocytes in addition to its action 
on asexual stages. This effect of 
artemether-lumefantrine gives it a 
signiﬁ  cant advantage over CQ/SP, 
although in terms of parasitological 
and clinical failure no difference was 
found between the two regimens.
Scaling Up Artemisinin-Based 
Combination Treatment
Whilst there is little argument that 
artemisinin-based combination 
treatments (ACTs) such as artemether-
lumefantrine are effective in treating 
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malaria, they are a lot more expensive 
than the treatments currently being 
used. The advocates of policy change 
are lobbying hard for the global 
ﬁ  nancing mechanisms that will likely 
be necessary in order to subsidize 
the world’s supply of ACTs [7]. The 
fervor of the advocates is intense [8], 
but national policies—particularly 
the introduction of interventions 
that are in short supply and cost 
more to produce—are unlikely to 
be implemented at the speed that a 
clinician treating an individual patient 
would desire. It is more likely that 
countries will explore the variety of 
strategic options open to them, which 
include ACTs as ﬁ  rst-line treatment, as 
well as non-artemisinin combination 
treatments, such as amodiaquine with 
SP, and will examine the potential 
beneﬁ  ts and costs [9]. 
With ACTs, the potential public 
health impact of reducing transmission 
is a factor to include in the evaluation 
of beneﬁ  ts versus costs, but there 
is little research on this impact in 
areas that are highly endemic for 
malaria. The ﬁ  nding of Sutherland 
and colleagues that ACTs also greatly 
reduce infectiousness will contribute 
to appropriate and informed decision-
making for sustainable changes in 
treatment policy at the country level.  
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